PFI:AIR - TT: Blood Typing Device without Reagents: Sensing Electrodes to Replace Optics

这个PFI：AIR技术翻译项目专注于翻译电动芯片实验室血型鉴定技术，以满足献血地点和救灾情况下对快速血型鉴定的需求。该项目将产生一种概念验证血型微型设备，可以在不使用显微镜的情况下同时检测细胞特征。该血型检测仪具有携带方便、ABO-Rh血型鉴定快速、无需试剂、可同时测定红细胞压积、血量小等特点。与纸质血液凝集试剂盒相比，这些功能提供了以下优势：节省时间和成本、提高效率、更长的保存期和更好的可靠性。纸质血凝试剂盒是该市场领域的主要竞争对手。虽然大多数电动/微流控设备适合手持显微镜载玻片，但操作该设备的支持基础设施包括相当大的成本和空间占用。该项目通过开发传感电极来解决这一技术差距，以取代光学显微镜？S在微设备中记录红细胞反应的角色，促进了从研究发现向用户友好的商业应用过渡的关键一步。这种血型微型设备很重要，因为创伤中心和医院广泛依赖美国各地血库提供的献血来拯救生命。目前，美国每年有8400万例血型测定，每年约有1600万例献血。每品脱血液的处理成本接近200美元，因此根据血型预先筛选捐赠者并有选择地指导献血过程(即血浆、红细胞)的能力将大大节省成本，并支持我们不断下降的血液供应。这项便携技术还可以转移到偏远的地理位置，用于救灾应用。此外，潜在的初步经济影响预计高达每年1200万美元，这将有助于美国在包括创伤、血液治疗和手术在内的医疗保健领域的竞争力。

This PFI: AIR Technology Translation project focuses on translating electrokinetic lab-on-a-chip blood typing technology to fill the need for rapid blood typing at blood donor sites and in disaster relief situations. The project will result in a proof-of-concept blood typing microdevice to simultaneously detect cell signatures without a microscope. This blood typing microdevice has the following unique features: portability, rapid ABO-Rh type identification, no reagents, simultaneous hematocrit determination, and small blood volumes. These features provide the following advantages: time- and cost-savings, increased efficiency, longer shelf life, and better reliability when compared to paper-based blood agglutination kits, the leading competitor in this market space. While most electrokinetic/microfluidic devices fit on handheld microscope slides, the supporting infrastructure to operate the device comprises a considerable cost and space footprint. This project addresses this technology gap by developing sensing electrodes to replace the optical microscope?s role of recording red blood cell responses in the microdevice, facilitating a key step in the transition from research discovery toward a user-friendly commercial application. This blood typing microdevice is important because trauma centers and hospitals rely extensively on blood donations provided by blood banks across the U.S to save lives. There are currently 84 million blood typings per year in the U.S., with approximately 16 million donations annually. Processing costs approach $200 per pint of blood, so the ability to pre-screen donors by blood type and selectively direct the donation process (i.e. plasma, red cells) would result in significant savings and bolster our declining blood supply. This portable technology could also be translated to remote geographical locations for disaster relief applications. In addition, the potential initial economic impact is expected to be up to $12 million per year, which will contribute to the U.S. competitiveness in healthcare including trauma, blood therapies, and surgeries.